HER2 Inhibitors Drug Class to Hold Largest Share in Global Breast Cancer Therapeutics Market by 2020, iHealthcareAnalyst, Inc.
Maryland Heights, MO, January 18, 2017 --(PR.com)-- While, Aromatase Inhibitors is the fastest growing segment of the market, HER2 inhibitors segment is likely to hold the largest share of the breast cancer therapeutics market. The HER2 inhibitors are mainly used as neoadjuvant treatment of patients with HER2 positive breast cancer at early stages and for advanced metastatic breast cancer (MBC) greater than 2 cm in diameter in size. The global breast cancer therapeutics market to reach nearly USD 12.8 Billion in 2020, at a CAGR of 8.5% from 2016 to 2020, due to higher incidence and rising prevalence of breast cancers.
Breast cancer therapeutics include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Breast cancer is the most common type of invasive cancer affecting women, and it is the most common cause of cancer death among women worldwide. It usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. The malignant type of tumor can spread to other cells present in the body. North America dominates market share for breast cancer therapeutics considering highest prevalence rate, modern medical technologies, health insurance coverage, and optimum per capita income.
Browse Breast Cancer Therapeutics Market – Drug Classes – Brand Name (Chemical Name) – Antimetabolites – Gemzar (Gemcitabine), Aromatase Inhibitors – Afinitor (Everolimus), Arimidex (Anastrozole), Aromasin (Exemestane), Femara (Leterozole), Ibrance (Palbociclib); Her2 Inhibitors – Herceptin (Trastuzumab), Kadcyla (Ado-Trastuzumab Emtansine), Perjeta (Pertuzumab), Tykerb (Lapatinib); Hormone Receptors – Fareston, Faslodex, Zoladex; and Mitotic Inhibitors – Halaven (Eribulin), Ixempra (Ixabepilone), Taxotere (Docetaxel) 2016-2020 at https://www.ihealthcareanalyst.com/report/breast-cancer-therapeutics-market/
The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes – brand name (chemical name) such as antimetabolites – Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020). The global breast cancer therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global breast cancer therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global breast cancer therapeutics market and included in this report are AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., Teva Pharmaceutical Industries Ltd.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/breast-cancer-therapeutics-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Breast cancer therapeutics include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Breast cancer is the most common type of invasive cancer affecting women, and it is the most common cause of cancer death among women worldwide. It usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. The malignant type of tumor can spread to other cells present in the body. North America dominates market share for breast cancer therapeutics considering highest prevalence rate, modern medical technologies, health insurance coverage, and optimum per capita income.
Browse Breast Cancer Therapeutics Market – Drug Classes – Brand Name (Chemical Name) – Antimetabolites – Gemzar (Gemcitabine), Aromatase Inhibitors – Afinitor (Everolimus), Arimidex (Anastrozole), Aromasin (Exemestane), Femara (Leterozole), Ibrance (Palbociclib); Her2 Inhibitors – Herceptin (Trastuzumab), Kadcyla (Ado-Trastuzumab Emtansine), Perjeta (Pertuzumab), Tykerb (Lapatinib); Hormone Receptors – Fareston, Faslodex, Zoladex; and Mitotic Inhibitors – Halaven (Eribulin), Ixempra (Ixabepilone), Taxotere (Docetaxel) 2016-2020 at https://www.ihealthcareanalyst.com/report/breast-cancer-therapeutics-market/
The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes – brand name (chemical name) such as antimetabolites – Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020). The global breast cancer therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global breast cancer therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global breast cancer therapeutics market and included in this report are AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., Teva Pharmaceutical Industries Ltd.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/breast-cancer-therapeutics-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories